

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 26, No 15

C O N T E N T S

May 20, 2008

Celebrating 25 Years of JCO

FROM JCO 1983

Doxorubicin, Mitomycin-C, and 5-Fluorouracil (DMF) in the Treatment of Metastatic Hormonal Refractory Adenocarcinoma of the Prostate, With a Note on the Staging of Metastatic Prostate Cancer

Christopher J. Logothetis, Melvin L. Samuels, Andrew C. von Eschenbach, Antonio Trindade, Sheryl Ogden, Cindy Grant, and Douglas E. Johnson c127

COMMENTARY

Chemotherapy for Advanced Prostate Cancer: 25 Years Later

Christopher J. Logothetis and Randall Millikan 2423

Editorials

Introducing New Treatments and Technologies Into the Clinic

The Editors of *Journal of Clinical Oncology* (see articles on pages 2436 and 2438, and correspondence on pages 2590, 2592, and 2593) 2425

Molecular Selection of Patients for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Inhibitors: Not Quite Ready for Prime Time

Frances A. Shepherd (see article on page 2442) 2426

Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux

Vicki L. Keedy, Carlos L. Arteaga, and David H. Johnson (see article on page 2450) 2428

Losing Sleep Over Cancer

David Spiegel (see article on page 2464) 2431

Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer

D. Craig Allred (see article on page 2473) 2433

Comments and Controversies

Protons and Parachutes

Joel E. Tepper (see editorial on page 2425, article on page 2438, and correspondence on pages 2590, 2592, and 2593) 2436

Should Randomized Clinical Trials Be Required for Proton Radiotherapy? An Alternative View

Eli Glatstein, John Glick, Larry Kaiser, and Stephen M. Hahn (see editorial on page 2425, article on page 2436, and correspondence on pages 2590, 2592, and 2593) 2438

Clinical Trial Investigator Status: You Need to Earn It

Nicholas J. Petrelli, Stephen Grubbs, and Kandie Price 2440

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 330 John Carlyle St, Suite 300, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 330 John Carlyle St, Suite 300, Alexandria, VA 22314.

2008 annual subscription rates, effective January 1, 2008: United States and possessions: individual, \$535; single issue, \$40. International: individual, \$735; single issue, \$50. Institutions: Tier 1: \$735 US, \$1,015 Int'l; Tier 2: \$855 US, \$1,135 Int'l; Tier 3: \$1,235 US, \$1,505 Int'l; Tier 4: \$1,360 US, \$1,630 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$265; all other countries, \$365. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

Original Reports

THORACIC ONCOLOGY

- ⓘ **First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic *EGFR* Mutations**
Lecia V. Sequist, Renato G. Martins, David Spigel, Steven M. Grunberg, Alexander Spira, Pasi A. Jänne, Victoria A. Joshi, David McCollum, Tracey L. Evans, Alona Muzikansky, Georgiana L. Kuhlmann, Moon Han, Jonathan S. Goldberg, Jeffrey Settleman, A. John Iafrate, Jeffrey A. Engelman, Daniel A. Haber, Bruce E. Johnson, and Thomas J. Lynch (see editorial on page 2426) 2442
- **Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023**
Karen Kelly, Kari Chansky, Laurie E. Gaspar, Kathy S. Albain, James Jett, Yee C. Ung, Derick H.M. Lau, John J. Crowley, and David R. Gandara (see editorial on page 2428) 2450
- ⓘ **Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non–Small-Cell Lung Cancer: CALGB 30105**
Mark A. Socinski, A. William Blackstock, Jeffrey A. Bogart, Xiaofei Wang, Michael Munley, Julian Rosenman, Lin Gu, Gregory A. Masters, Peter Ungaro, Arthur Sleeper, Mark Green, Antonius A. Miller, and Everett E. Vokes 2457

PALLIATIVE CARE

- Sleep/Wake Patterns of Individuals With Advanced Cancer Measured by Ambulatory Polysomnography**
Kathy P. Parker, Donald L. Bliwise, Maria Ribeiro, Sanjay R. Jain, Catherine I. Vena, Mary Kay Kohles-Baker, Andre Rogatko, Zhiheng Xu, and Wayne B. Harris (see editorial on page 2431) 2464

BREAST CANCER

- ⓘ **Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory**
Sunil S. Badve, Frederick L. Baehner, Robert P. Gray, Barrett H. Childs, Tara Maddala, Mei-Lan Liu, Steve C. Rowley, Steven Shak, Edith D. Perez, Lawrence J. Shulman, Silvana Martino, Nancy E. Davidson, George W. Sledge, Lori J. Goldstein, and Joseph A. Sparano (see editorial on page 2433) 2473
- ⓘ **Mammography Before Diagnosis Among Women Age 80 Years and Older With Breast Cancer**
Brian D. Badgwell, Sharon H. Giordano, Zhigang Z. Duan, Shenying Fang, Isabelle Bedrosian, Henry M. Kuerer, S. Eva Singletary, Kelly K. Hunt, Gabriel N. Hortobagyi, and Gildy Babiera 2482

HEAD AND NECK CANCER

- ⓘ **Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma**
David M. Brizel, Barbara A. Murphy, David I. Rosenthal, Kishan J. Pandya, Stefan Glück, Herbert E. Brizel, Ruby F. Meredith, Dietmar Berger, Mon-Gy Chen, and William Mendenhall 2489

GENITOURINARY CANCER

- **Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer**
Eric M. Horwitz, Kyoung-hwa Bae, Gerald E. Hanks, Arthur Porter, David J. Grignon, Harmar D. Brereton, Varagur Venkatesan, Colleen A. Lawton, Seth A. Rosenthal, Howard M. Sandler, and William U. Shipley 2497

HEMATOLOGIC MALIGNANCIES

- **Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy**
Elaine M. Sloand, Colin O. Wu, Peter Greenberg, Neal Young, and John Barrett 2505
- **Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire**
Carole Soussain, Khê Hoang-Xuan, Luc Taillandier, Emmanuelle Fourme, Sylvain Choquet, Francis Witz, Olivier Casasnovas, Brigitte Dupriez, Bertrand Souleau, Anne-Laure Taksin, Christian Gisselbrecht, Arnaud Jaccard, Antonio Omuro, Marc Sanson, Maud Janvier, Brigitte Kolb, Jean-Marc Zini, and Véronique Leblond 2512

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia	2519
Leslie A. Andritsos, Amy J. Johnson, Gerard Lozanski, William Blum, Cheryl Kefauver, Farrukh Awan, Lisa L. Smith, Rosa Lapalombella, Sarah E. May, Chelsey A. Raymond, Da-Sheng Wang, Robert D. Knight, Amy S. Ruppert, Amy Lehman, David Jarjoura, Ching-Shih Chen, and John C. Byrd	

GASTROINTESTINAL CANCER

Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head	2526
Stefan Heinrich, Bernhard C. Pestalozzi, Markus Schäfer, Achim Weber, Peter Bauerfeind, Alexander Knuth, and Pierre-Alain Clavien	

Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?	2532
Nancy L. Keating, Mary Beth Landrum, Carrie N. Klabunde, Robert H. Fletcher, Selwyn O. Rogers, William R. Doucette, Diana Tisnado, Steven Clauser, and Katherine L. Kahn	

SUPPORTIVE CARE AND QUALITY OF LIFE

Assessing 2-Month Clinical Prognosis in Hospitalized Patients With Advanced Solid Tumors	2538
Anne-Claire Barbot, Pascale Mussault, Pierre Ingrand, and Jean-Marc Tourani	

Pain Predicts Overall Survival in Men With Metastatic Castration-Refractory Prostate Cancer	2544
Susan Halabi, Nicholas J. Vogelzang, Alice B. Kornblith, San-San Ou, Philip W. Kantoff, Nancy A. Dawson, and Eric J. Small	

AIDS-RELATED CANCER

HIV-Specific Differences in Outcome of Squamous Cell Carcinoma of the Anal Canal: A Multicentric Cohort Study of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy	2550
Christoph Oehler-Jänne, Florence Huguet, Sawyna Provencher, Burkhardt Seifert, Laura Negretti, Marc-Oliver Riener, Marta Bonet, Abdelkarim S. Allal, and I. Frank Ciernik	

GYNECOLOGIC CANCER

Histologic Results of Para-Aortic Lymphadenectomy in Patients Treated for Stage IB2/II Cervical Cancer With Negative [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scans in the Para-Aortic Area	2558
Mathias Boughanim, Sophie Leboulleux, Annie Rey, Chi Tuan Pham, Yaelle Zafrani, Pierre Duvillard, Jean Lumbroso, Christine Haie-Meder, Martin Schlumberger, and Philippe Morice	

ASCO Special Article

American Society of Clinical Oncology Statement on Minimum Standards and Exemplary Attributes of Clinical Trial Sites	2562
Robin Zon, Neal J. Meropol, Robert B. Catalano, and Richard L. Schilsky	

Biology of Neoplasia

Basal-Like Breast Cancer: A Critical Review	2568
Emad A. Rakha, Jorge S. Reis-Filho, and Ian O. Ellis	

Diagnosis in Oncology

Bilateral Eardrum Perforation After Long-Term Treatment With Erlotinib	2582
Slow Ming Lee, Tomas Buchler, Theo Joseph, and Cecilia Lai	

Rituximab-Induced Hepatitis C Virus Reactivation After Spontaneous Remission in Diffuse Large B-Cell Lymphoma	2584
Ching-Yun Hsieh, Hsin-Hui Huang, Chen-Yuan Lin, Lo Woei Chung, Yu-Mine Liao, Li-Yuan Bai, and Chang-Fang Chiu	

Management of a Presacral Teratoma in an Adult	2586
Susana C. Wishnia, Jennifer E. Rosen, M. Adel Hamid, Susan Haas, and Nilda Moreno-Ruiz	

Correspondence

On Equipose and Emerging Technologies	2590
Brett E. Lewis (see editorial on page 2425, articles on pages 2436 and 2438, and correspondence on pages 2590, 2592, and 2593)	

■ Proton Therapy Should Be Tested in Randomized Trials Fergus R. Macbeth and Michael V. Williams (see editorial on page 2425, articles on pages 2436 and 2438, and correspondence on pages 2590, 2592 and 2593)	2590
■ A Patient's Perspective on Randomized Clinical Trials for Proton Radiotherapy James P. Morgan (see editorial on page 2425, articles on pages 2436 and 2438, and correspondence on pages 2590, 2592, and 2593)	2592
■ In Reply Michael Brada, Dirk De Ruyscher, and Madelon Pijls-Johannesma (see editorial on page 2425, articles on pages 2436 and 2438, and correspondence on pages 2590, 2592, and 2593)	2592
■ In Reply Michael Goitein and James D. Cox (see editorial on page 2425, articles on pages 2436 and 2438, and correspondence on pages 2590 and 2592)	2593
Hormone Receptor, Grade, Human Epidermal Growth Factor Receptor 2, and Topoisomerase II As Predictors of Response to Chemotherapy Rita S. Mehta	2596
In Reply Kathleen I. Pritchard, Maureen Trudeau, Hans Messersmith, Leela Elavathil, Frances O'Malley, and Bindi Dhesy-Thind	2596
Hepatic Arterial Infusion: A Treatment at the "End of an Era"? Derek G. Power and Gregory D. Leonard	2597
In Reply Simone Mocellin	2598
Effect of Epoetin on Survival in Patients With Breast Cancer Giovanni Codacci-Pisanelli, Gian Paolo Spinelli, and Silverio Tomao	2599
In Reply Matti S. Aapro	2599
Should KRAS Mutations Be Considered an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab? Marina Chiara Garassino, Gabriella Farina, Antonio Rossi, Olga Martelli, and Valter Torri	2600
In Reply Astrid Lièvre and Pierre Laurent-Puig	2601
Is Single-Agent Chemotherapy Acceptable in Platinum-Sensitive Relapsed Ovarian Cancer? Rony M. Abou-Jawde and Satinderjit S. Oberoi	2602
In Reply Gabriella Ferrandina, Manuela Ludovisi, Giovanni Scambia, and Sandro Pignata	2603
Errata	2604

Also in This Issue

[Information for Subscribers](#)

[Announcements](#)

[Information for Contributors](#)

[Manuscript Submission Checklist](#)

[Current Abstracts](#)

[Calendar of Oncology Events](#)



Online supplementary information available at www.jco.org



Article was published online ahead of print at www.jco.org